Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

View from ESMO: iTeos data keep TIGIT alive, for now

Plus readouts from Genmab, AstraZeneca, Merck, Astellas and more

September 18, 2024 12:55 AM UTC

iTeos has delivered another Phase II win for cancer immunotherapy target TIGIT, but with the readout comes some of the same questions and concerns that have contributed to the mechanism’s past failures to translate to Phase III success.

iTeos Therapeutics Inc. (NASDAQ:ITOS) reported at the ESMO Congress in Barcelona that first-line treatment with its Fc-enabled TIGIT blocker belrestotug plus PD-1 mAb Jemperli dostarlimab more than doubled the objective response rate over Jemperli alone in patients with PD-L1-high non-small cell lung cancer (NSCLC). The company reported an overall response rate of about 60% for each of the three doses tested in the Phase II GALAXIES Lung-201 study, compared with a confirmed ORR of 28% in the Jemperli arm...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article